Jennifer Reimer, DO
Internal Medicine · Point Pleasant Boro, NJNPI 1558651208
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 360 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 21.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,493 and has fallen 53.1% since, to $1,169 in 2025. Among internal medicine clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 360 payments — averaging $18.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$1K
- AbbVie$651
- Lilly USA, LLC$637
- Pfizer$611
- GSK$319
- plus $2K from 29 others
What the payments were for
- Food & beverage$6,739100%
- Education$60%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 41 | $1,450 |
| Novo Nordisk | 69 | $1,145 |
| AbbVie(2 entities) | 38 | $651 |
| Lilly USA, LLC | 37 | $637 |
| Pfizer | 37 | $611 |
| GSK | 15 | $319 |
| Exact Sciences | 11 | $279 |
| Merck | 19 | $254 |
| Amgen(2 entities) | 16 | $234 |
| Axsome Therapeutics, Inc. | 2 | $143 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $139 |
| Amarin Pharma, Inc. | 6 | $82 |
| Kowa Pharmaceuticals America, Inc. | 6 | $80 |
| Radius Health, Inc. | 5 | $63 |
| Bayer | 3 | $62 |
| Boehringer Ingelheim | 4 | $60 |
| Genentech USA, Inc. | 4 | $55 |
| Abbott | 3 | $52 |
| Sanofi Pasteur Inc. | 3 | $43 |
| IBSA Pharma Inc. | 3 | $41 |
| Arbor Pharmaceuticals, Inc. | 3 | $40 |
| Dynavax Technologies Corporation | 2 | $37 |
| Teva Pharmaceuticals USA, Inc. | 3 | $35 |
| Supernus Pharmaceuticals, Inc. | 2 | $33 |
| Phathom Pharmaceuticals, Inc. | 2 | $32 |
| Johnson & Johnson | 2 | $29 |
| Novartis | 1 | $24 |
| Biohaven Pharmaceuticals, Inc. | 1 | $17 |
| E.r. Squibb & Sons, L.L.C. | 1 | $16 |
| Indivior Inc. | 1 | $15 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Amneal Pharmaceuticals LLC | 1 | $15 |
| Astellas Pharma US Inc | 1 | $14 |
| Endo Pharmaceuticals Inc. | 1 | $14 |
| Bausch Health US, LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,745 in reported general payments places this provider in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 52 | $109,934 |
| MounjaroTirzepatide | 80 | $103,054 |
| FarxigaDapagliflozin Propanediol | 76 | $89,552 |
| JardianceEmpagliflozin | 26 | $42,531 |
| EliquisApixaban | 24 | $23,578 |
| Repatha SureclickEvolocumab | 29 | $20,953 |
| Repatha SyringeEvolocumab | 16 | $12,564 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $11,333 |
| VascepaIcosapent Ethyl | 12 | $9,362 |
| Icosapent Ethyl | 11 | $8,621 |
| SynthroidLevothyroxine Sodium | 77 | $7,233 |
| Rosuvastatin Calcium | 289 | $5,247 |
| Olmesartan Medoxomil | 116 | $3,932 |
| Ezetimibe | 84 | $3,723 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 90 | $2,560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,145 | $109,93452 claims |
| Lilly USA, LLCMounjaro | $637 | $103,05480 claims |
| AstraZenecaFarxiga | $1,450 | $89,55276 claims |
| Boehringer IngelheimJardiance | $60 | $42,53126 claims |
| PfizerEliquis | $611 | $23,57824 claims |
| GSKBreo Ellipta | $319 | $11,33316 claims |
| AbbVieSynthroid, Armour Thyroid | $651 | $8,37895 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $15 | $1,969219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Point Pleasant Boro
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.